EC Number   |
Expression |
Reference |
|---|
   1.14.13.39 | down |
0.01 mM 2-phenyl-ethenesulfonic acid phenyl ester, 2-phenyl-ethenesulfonic acid 4-chlorophenyl ester, and 2-methyl-4-nitro-quinoline 1-oxide inhibit the expression of inducible nitric oxide synthase protein, 4-nitro-quinoline 1-oxide reveals no significant expression-downregulating activity at 0.01 mM |
696643 |
| 1.14.13.39 | down |
0.1 mg 6-n-propyl-2-thyouracil decreases nNOS protein level to 19% compared to control |
700433 |
| 1.14.13.39 | down |
expression of eNOS mRNA and protein does not change in mild to moderate chronic obstructive pulmonary disease, but is reduced in the more severe stages of chronic obstructive pulmonary disease |
695513 |
| 1.14.13.39 | down |
expression of isozyme NOS1 protein is decreased in the cytoplasmic and plasma membrane fractions, although maintained in the intracellular membrane fraction, in response to high salt |
697412 |
| 1.14.13.39 | down |
in Portunus trituberculatus challenged with the Hematodinium parasite, transcripts in hemocytes are significantly induced at 12 and 24 h, followed by significant suppression at 96 and 192 h |
744948 |
| 1.14.13.39 | down |
mitogen-activated protein kinase phosphatase-1 may negatively regulate iNOS expression by controlling the expression of microRNA-155 and consequently the signal transducer and activator of transcription pathway via suppressor of cytokine signaling-1 |
698939 |
| 1.14.13.39 | down |
nitric oxide synthase activity and expression are decreased in the paraventricular nucleus of pregnant rats |
697042 |
| 1.14.13.39 | more |
expression of isozyme NOS3 protein is unaffected by high salt |
697412 |
| 1.14.13.39 | more |
neither interleukin-1 nor tissue necrosis factor-alpha is capable of inducing nNOS synthesis for up to 48 h treatment, treatment with insulin-like growth factor-1 or transforming growth factor-beta for up to 48 h has no effect on the levels of nNOS |
700490 |
| 1.14.13.39 | more |
treatment with a selective G protein-coupled ER agonist decreases NADPH-diaphorase expression in the supraoptic and paraventricular nuclei of the hypothalamus. Treatment with the selective G protein-coupled estrogen receptor agonist in combination with an antagonist effectively rescues the decrease in NADPH-diaphorase expression in both brain regions |
743357 |
